Invest now
Morepen Laboratories share price
High risk
You have to be logged in to add this to Watchlist.- ₹84.22(4.22%)August 14, 2026 15:54:58 PM IST
- NSE
- BSE
- Vol : 42.30 M (NSE + BSE)Last 20 day avg : 27.13 M
Morepen Laboratories is trading 4.22% upper at Rs 84.22 as compared to its last closing price. Morepen Laboratories has been trading in the price range of 84.79 & 78.28. Morepen Laboratories has given 96.96% in this year & 1.85% in the last 5 days. Morepen Laboratories has TTM P/E ratio 23.09 as compared to the sector P/E of 33.00.The company posted a net profit of 56.40 Crores in its last quarter.Listed peers of Morepen Laboratories include Sun Pharmaceutical Industries (-0.92%), Divi's Laboratories (-%), Torrent Pharmaceuticals (-0.74%).The Mutual Fund holding in Morepen Laboratories was at 0.05% in 30 Sep 2023. The MF holding has - from the last quarter. The FII holding in Morepen Laboratories was at 1.46% in 30 Jun 2026. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 17 Aug 2026, 04:11 AM IST
- BetaHigh volatility1.74Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.17The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.25Annual dividends as a percentage of the stock price.
- P/BHigher than historical values3.56The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/ELower than historical values31.60Price-to-earnings ratio based on trailing 12-month earnings
- PEG RatioIndicates Fair Valuation1.02The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Morepen Laboratories News
Morepen Laboratories Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,924.90 | -0.92 | 4,61,837.11 | 38.40 | 5.55 | 0.83 | 0.47 |
| Divi's Laboratories | 8,500.00 | - | 2,25,648.29 | 73.32 | 11.48 | 0.41 | 0.03 |
| Torrent Pharmaceuticals | 4,840.30 | -0.74 | 1,84,102.87 | 72.73 | 19.22 | 0.80 | 141.16 |
| Cipla | 1,450.00 | -0.75 | 1,17,138.71 | 27.57 | 3.33 | 0.92 | 1.11 |
| Zydus Lifesciences | 1,140.00 | -2.81 | 1,13,715.44 | 21.19 | 4.24 | 0.09 | 14.22 |
Mutual Fund Ownership
View allMorepen Laboratories Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-08-04 | Quarterly Results |
| 2026-05-26 | Audited Results & Final Dividend |
| 2026-05-22 | Audited Results |
| 2026-02-10 | Quarterly Results |
| 2025-11-14 | Quarterly Results |
About the company Morepen Laboratories
- IndustryBiotechnology & Drugs
- ISININE083A01026
- BSE Code500288
- NSE CodeMOREPENLAB
Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Fexofenadine, Montelukast (Oral), Montelukast (Chewable), Montelukast Sodium, among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen Nebulizer Model CN-11, Dr. Morepen Pulse Oximeter Model PO-12A, Dr. Morepen Breathe Free Vaporizer Model VP-06 and Dr. Morepen Pulse Oximeter Model PO-12A, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.
Morepen Laboratories Share Price FAQs
Morepen Laboratories is trading at 84.22 as on Fri Aug 14 2026 10:24:58. This is 4.22% upper as compared to its previous closing price of 80.81.
The market capitalization of Morepen Laboratories is 4614.86 Cr as on Fri Aug 14 2026 10:24:58.
The 52 wk high for Morepen Laboratories is 83.45 whereas the 52 wk low is 33.44
Morepen Laboratories can be analyzed on the following key metrics -
- TTM P/E: 23.09
- Sector P/E: 33.00
- Dividend Yield: 0.25%
- D/E ratio: -
Morepen Laboratories reported a net profit of 94.88 Cr in 2026.
The Mutual Fund Shareholding was 0.05% at the end of 30 Sep 2023.
Quick Links
EQUITY QUICK LINKS
Morepen Laboratories QUICK LINKS
FROM MARKETS
RELATED LINKS
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.